Management of thyroid emergencies: joint consensus statement on management of thyroid storm*

European thyroid journal · 2026 · DACH

Source and licence

Authors
Peter Taylor, Onyebuchi Okosieme, Grigoris Effraimidis et al.
Title
Management of thyroid emergencies: joint consensus statement on management of thyroid storm*
Journal
European Thyroid Journal, 2026
Licence
CC BY 4.0
Changes
Verbatim excerpts; formatting adapted

Full text retrieved 2026-10-27 from Europe PMC · PMC13506520

Licence statement of the original publication

This work is licensed under a Creative Commons Attribution 4.0 International License.

This page reproduces excerpts of the original publication; the original is authoritative. It has not been reviewed by a physician, does not state a recommendation of Medelix and does not replace medical advice. The guideline may have been updated since.

Open the original publication →Full text on Europe PMC

Recommendations

We found no explicitly labelled recommendations in this publication; its recommendations are in the running text of the original.

Abstract

Thyroid storm is a rare but life-threatening endocrine emergency characterised by extreme thyrotoxicosis and multi-organ dysfunction. Prompt recognition and rapid, coordinated management are essential to reduce its high mortality. This consensus statement, developed by experts in endocrinology and acute care, provides practical recommendations for the diagnosis and treatment of thyroid storm. Diagnosis remains clinical, aided by validated scoring systems such as the Burch–Wartofsky and Japanese Thyroid Association/Japan Endocrine Society criteria, which also predict outcomes. Management requires a multidisciplinary approach in high-dependency or intensive care settings, incorporating supportive measures, aggressive treatment of precipitating factors, and targeted therapies. Core treatments include beta-blockade, high-dose antithyroid drugs, corticosteroids, and iodide, with careful attention to timing and contraindications. Adjunctive therapies, such as cholestyramine, lithium, plasmapheresis, and extracorporeal membrane oxygenation (ECMO), as well as surgical thyroidectomy in selected cases, may be required for refractory disease. This guidance also highlights the need for definitive management of underlying hyperthyroidism after stabilisation. By summarising current evidence and expert consensus, this document aims to standardise care, support clinical decision-making, and improve outcomes in patients presenting with thyroid storm.

Contents of the original publication

The section headings of the original.

  • Introduction
  • Methods
  • Recognition and diagnosis
  • Treatment
  • General measures
  • Beta-blockade
  • Antithyroid drugs
  • Corticosteroids
  • Iodine/potassium iodide
  • Ongoing management
  • Rarely used or context-specific therapies
  • Disclaimer

A question about this guideline?

Medelix answers clinical questions from guidelines and studies – every statement with its source.

Are you the rights holder and object to this reproduction? Write to contact@medelix.ai and we will take the page down promptly. Imprint